Investment accounts
Adult accounts
Child accounts
Choosing Fidelity
Choosing Fidelity
Why invest with us Current offers Fees and charges Open an account Transfer investments
Financial advice & support
Fidelity’s Services
Fidelity’s Services
Financial advice Retirement Wealth Management Investor Centre (London) Bereavement
Guidance and tools
Guidance and tools
Choosing investments Choosing accounts ISA calculator Retirement calculators
Share dealing
Choose your shares
Tools and information
Tools and information
Share prices and markets Chart and compare shares Stock market news Shareholder perks
Pensions & retirement
Pensions, tax & tools
Saving for retirement
Approaching / In retirement
Approaching / In retirement
Speak to a specialist Creating a retirement plan Taking tax-free cash Pension drawdown Annuities Investing in retirement Investment Pathways
FTSE 100 movers: Bunzl in the red; Dechra gains on acquisition
(Sharecast News) - London's FTSE 100 was down 0.4% at 7,397.80 in afternoon trade on Tuesday. NatWest was the worst performer as its shares went ex-dividend.
Bunzl was in the red even as it lifted its full-year margin outlook and posted a jump in first-half profit and revenue as product cost inflation and volume growth more than offset an expected decline in Covid-related sales.
AstraZeneca was also weaker despite saying that its Evusheld long-acting antibody combination has been approved in Japan for the prevention and treatment of Covid-19. It also said on Tuesday that clinical trial results had shown that its Farxiga treatment against Type II diabetes significantly reduced the risk of cardiovascular death or worsening of heart failure in patients with mildly reduced or preserved ejection fraction.
Dechra Pharmaceuticals was sitting pretty at the top of the index after announcing the acquisition of bought California -based veterinary pharmaceutical manufacturer Med-Pharmex for $260m (£221.5m). It said Med-Pharmex is the acquisition referred to in the fundraising announcement it made in July as the "potential acquisition".
Next was also up after Joules said it remains in "positive" discussions with the retailer about adopting its Total Platform services to support its long-term growth plans and a potential equity investment.
The company, which first announced the talks earlier this month, was responding to a Sky News report over the weekend suggesting that the struggling fashion chain's talks with Next had hit a stumbling block after Joules issued a profit warning.
FTSE 100 - Risers
Dechra Pharmaceuticals (DPH) 3,580.00p 4.07% Smurfit Kappa Group (CDI) (SKG) 2,896.00p 3.35% JD Sports Fashion (JD.) 112.85p 2.92% Smith (DS) (SMDS) 268.00p 2.80% Next (NXT) 5,892.00p 2.79% Kingfisher (KGF) 236.60p 2.78% Pershing Square Holdings Ltd NPV (PSH) 2,830.00p 2.72% Sainsbury (J) (SBRY) 207.90p 2.57% Entain (ENT) 1,278.00p 2.53% Barclays (BARC) 166.06p 2.44%
FTSE 100 - Fallers
NATWEST GROUP (NWG) 252.05p -6.72% Endeavour Mining (EDV) 1,682.00p -5.61% Bunzl (BNZL) 2,944.00p -5.49% Centrica (CNA) 78.10p -4.71% Harbour Energy (HBR) 473.40p -3.80% SSE (SSE) 1,739.00p -3.52% Fresnillo (FRES) 707.40p -2.86% Haleon (HLN) 259.40p -2.59% BAE Systems (BA.) 794.80p -2.24% AstraZeneca (AZN) 11,122.00p -2.13%
Share this article
Related Sharecast Articles
Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.
Award-winning online share dealing
Search, compare and select from thousands of shares.
Expert insights into investing your money
Our team of experts explore the world of share dealing.
Policies and important information
Accessibility | Conflicts of interest statement | Consumer Duty Target Market | Consumer Duty Value Assessment Statement | Cookie policy | Diversity and Inclusion | Doing Business with Fidelity | Fidelity gender pay report | Investing in Fidelity funds | Legal information | Modern slavery | Mutual respect policy | Privacy statement | Remuneration policy | Security | Statutory and Regulatory disclosures | Whistleblowing policy
Please remember that past performance is not necessarily a guide to future performance, the performance of investments is not guaranteed, and the value of your investments can go down as well as up, so you may get back less than you invest. When investments have particular tax features, these will depend on your personal circumstances and tax rules may change in the future. This website does not contain any personal recommendations for a particular course of action, service or product. You should regularly review your investment objectives and choices and, if you are unsure whether an investment is suitable for you, you should contact an authorised financial adviser. Before opening an account, please read the ‘Doing Business with Fidelity’ document which incorporates our client terms. Prior to investing into a fund, please read the relevant key information document which contains important information about the fund.
This website is issued by Financial Administration Services Limited, which is authorised and regulated by the Financial Conduct Authority (FCA) (FCA Register number 122169) and registered in England and Wales under company number 1629709 whose registered address is Beech Gate, Millfield Lane, Lower Kingswood, Tadworth, Surrey, KT20 6RP.
